ACHV - Achieve Life Sciences, Inc.
| Previous Close | 0.5995 |
| Open | 0.6300 |
| Bid | 0.6285 x 2200 |
| Ask | 0.6450 x 800 |
| Day's Range | 0.6140 - 0.6699 |
| 52 Week Range | 0.4600 - 4.6300 |
| Volume | 6,803,939 |
| Avg. Volume | 1,838,838 |
| Market Cap | 15.968M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3450 |
| Earnings Date | Mar 11, 2020 - Mar 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- PR Newswire
Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
Achieve Life Sciences, Inc. (Nasdaq: ACHV), University of Bristol, and Oracle Corporation (NYSE: ORCL) today announced the outcome of a study using Oracle's high-performance cloud infrastructure to potentially improve the speed of drug discovery and development of new treatments.
- Simply Wall St.
Here's Why We're A Bit Worried About Achieve Life Sciences's (NASDAQ:ACHV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
CNW GroupAchieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
SEATTLE and VANCOUVER, British Columbia , Dec. 19, 2019 /CNW/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million , which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering was comprised of Class A units, priced at a public offering price of $0.60 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $0.60 per share, and Class B units, priced at a public offering price of $999.60 per unit, with each unit comprised of one share of Series B preferred stock, which is convertible into 1,666 shares of common stock, and a five-year warrant to purchase 1,666 shares of common stock, also with an exercise price of $0.60 per share.
- CNW Group
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
SEATTLE and VANCOUVER, British Columbia , Dec. 17, 2019 /CNW/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million , prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering is comprised of Class A units, priced at a public offering price of $0.60 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $0.60 per share, and Class B units, priced at a public offering price of $999.60 per unit, with each unit comprised of one share of Series B preferred stock, which is convertible into 1,666 shares of common stock, and a five-year warrant to purchase 1,666 shares of common stock, also with an exercise price of $0.60 per share.
- CNW Group
Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
SEATTLE and VANCOUVER, British Columbia , Dec. 9, 2019 /CNW/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced an update on the cytisinicline clinical development program. Following discussions with the Food and Drug Administration (FDA), Achieve has received feedback on the final Phase 3 clinical trial protocols and the cytisinicline clinical development program. Specifically, the FDA has agreed with the overall Phase 3 study designs that will utilize the simplified cytisinicline dosing schedule of 3.0 mg administered three times daily and the duration of 6 and 12 weeks of treatment.
- Zacks Small Cap Research
ACHV: After Capital Raise Ready for Phase III
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Third Quarter 2019 Operational and Financial Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) released its third quarter results for 2019 and filed the companion 10-Q on November 6, 2019. An S-1 was simultaneously issued targeting a $10 million raise in order to partially fund the upcoming Phase III trials. Following the
- PR Newswire
Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia , Nov. 6, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- CNW Group
Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
- Simply Wall St.
What Type Of Shareholder Owns Achieve Life Sciences, Inc.'s (NASDAQ:ACHV)?
Every investor in Achieve Life Sciences, Inc. (NASDAQ:ACHV) should be aware of the most powerful shareholder groups...
- PR Newswire
Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
"Successful Smoking Abstinence with Cytisinicline in the ORCA-1 Trial: What Happens Next?" will be presented at the SRNT-O meeting by Achieve's Chief Scientific Officer, Dr. Anthony Clarke, on Friday, October 25th in Sydney. The results of the ORCA-1 trial, to be discussed in the presentation, confirm that future Phase 3 clinical trials are expected to utilize 3.0 mg TID dosing of cytisinicline. The Company plans to extend dosing in the Phase 3 trials from 25 days to 42 days, or six weeks.
- PR Newswire
Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
SEATTLE and VANCOUVER, British Columbia, Sept. 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced completion of their maximum tolerated dose (MTD) study. The results indicate a lack of dose-limiting toxicity as defined by protocol criteria even at the highest 30 mg single, oral dose of cytisinicline evaluated in the study. This study, initiated in March 2019, is required by the FDA as part of a New Drug Application (NDA) for marketing approval in the United States.
- Zacks Small Cap Research
ACHV: Post Phase II Investor Day
By John Vandermosten, CFA NASDAQ:ACHV Achieve Life Sciences, Inc. (NASDAQ:ACHV) held its first investor day following the read out of the ORCA-1 trial on September 20, 2019. The event was introduced by CFO John Bencich and included a roundtable discussion moderated by analysts Michael Higgins of Ladenburg Thalmann and Jason McCarthy of Maxim Group. The key opinion
- PR Newswire
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two presentations featuring final data from the Phase 2b ORCA-1 trial will be conducted at the SRNT-E Annual Conference on Friday, September 13th in Oslo. Topline results, reported in June of 2019, have led to the selection of 3.0 mg, three times daily (TID) dosing for future Phase 3 development. The 3.0 mg TID treatment arm demonstrated a 54% abstinence rate at week 4, compared to 16% for placebo (p
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Achieve Life Sciences, Inc. (NASDAQ:ACHV)?
Anyone researching Achieve Life Sciences, Inc. (NASDAQ:ACHV) might want to consider the historical volatility of the...
- PR Newswire
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
The event will include an updated data presentation by the primary investigator of the Phase 2b ORCA-1 trial of cytisinicline. It will also feature a panel discussion moderated by leading healthcare analysts, Michael Higgins from Ladenburg Thalmann and Jason McCarthy from Maxim Group, with participation from four esteemed medical experts in the field of smoking cessation.
- CNW Group
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
